Liraglutide Improves Glycemic Control in Type 2 Diabetics Treated with Multiple Daily Insulin Injections

The injectable glucagon-like peptide-1–receptor agonist liraglutide (Victoza) improves glycemic control in patients with type 2 diabetes who are treated with oral antidiabetic drugs or basal insulin therapy. However, liraglutide has not been studied in patients who are receiving both basal and prandial insulin. In this study from Sweden, 124 such patients (mean age, 64; mean duration of diabetes, 17 years) were randomized to daily subcutaneous liraglutide (titrated to 1.8 mg) or placebo, added to their basal and prandial insulin. At baseline, mean glycosylated hemoglobin (HbA_1c) level was 9%, and mean body-mass index was 34 kg/m².

At 24 weeks, mean decreases in baseline HbA_1c level were greater in the liraglutide group than in the placebo gr…